Gilead (GILD) Files BLA for Bulevirtide for Hepatitis Delta Virus

Gilead (GILD) submits a biologics license application to the FDA for bulevirtide for the treatment of chronic hepatitis delta virus infection in adults with compensated liver disease.

Leave a comment

Your email address will not be published. Required fields are marked *